Theriva Biologics, Inc. (TOVX) Stock

Understand Theriva Biologics, Inc.: how it makes money

Theriva Biologics develops clinical-stage therapeutics for high unmet-need diseases, including SYN-004 (designed to degrade certain IV beta-lactam antibiotics in the GI tract to help prevent microbiome damage, CDI, AMR-related risks, and aGVHD) and SYN-020 (an oral recombinant formulation). In the provided facts, no current product sales are described, so near-term economics depend on advancing its drug candidates into later-stage development and eventual commercialization.

Because Theriva is a clinical-stage company, its path to profits depends on whether its lead candidates (SYN-004 and SYN-020) can progress successfully through development toward approval and commercialization.

Business quality (Weak): Based on the provided information, the business model and lead candidates are clear, but there are no official reportable segments or operating KPIs given, and revenue is shown as 0.0 in the latest quarter, limiting the ability to analyze operating drivers.

Bull case

• Focused pipeline in areas of high unmet need: SYN-004 is designed to degrade commonly used IV beta-lactam antibiotics in the GI tract, with stated goals including prevention of microbiome damage, CDI, overgrowth of pathogenic organisms, AMR emergence, and acute graft-versus-host-disease (aGVHD).
• Multiple targeted clinical problems from a single candidate strategy: The company describes SYN-004 as addressing several downstream outcomes related to antibiotic exposure and transplant-associated risk, which could broaden potential clinical and commercial relevance if validated.

Bear case

• Clinical-stage execution risk: The company is described as clinical-stage, which implies uncertainty around whether its candidates will produce the outcomes needed for later development and approval.
• No operating revenue in the provided quarter: For the quarter ended 2026-03-31, revenue is shown as 0.0 in the provided facts, while operating performance is deeply negative (operating margin -709.0).
• Limited visibility into operating drivers: No operational KPI labels are provided in the input facts, so there is not enough information here to track a specific, repeatable operational metric that supports the profit model.

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• BioVie Inc. (BIVI)
• Phio Pharmaceuticals Corp. (PHIO)
• Moleculin Biotech, Inc. (MBRX)
• Kiora Pharmaceuticals, Inc. (KPRX)
• Aspire Biopharma Holdings, Inc. (ASBP)
• Bullfrog AI Holdings, Inc. Common Stock (BFRG)
• MetaVia Inc. (MTVA)
• Imunon, Inc. (IMNN)